Clinical, morphologic, and cytogenetic characteristics of the included patients with AML at diagnosis
| Characteristic . | Value . |
|---|---|
| No. of patients | 69 |
| Median age at diagnosis, y (range), n = 67 | 9.1 (8.8; 0.3-16.5) |
| PT-BRWBC count, ×109/L, median (25-75 percentiles), n = 56 | 44.9 (16.6-155.9) |
| Sex, n (%) | |
| Female | 20 (29) |
| Male | 49 (71) |
| FAB classification, n (%) | |
| M0 | 5 (7) |
| M1 | 11 (16) |
| M2 | 14 (20) |
| M3 | 2 (3) |
| M4 | 16 (23) |
| M5 | 12 (17) |
| M6 | 1 (1) |
| M7 | 2 (3) |
| Unknown | 6 (9) |
| Cytogenetic subgroups | |
| AML-ETO1 | 7 (10) |
| MLL | 5 (7) |
| PML-RAR | 0 (0) |
| CBF-MYH | 2 (3) |
| CN-AML | 13 (19) |
| Other | 22 (32) |
| Unknown | 20 (29) |
| Characteristic . | Value . |
|---|---|
| No. of patients | 69 |
| Median age at diagnosis, y (range), n = 67 | 9.1 (8.8; 0.3-16.5) |
| PT-BRWBC count, ×109/L, median (25-75 percentiles), n = 56 | 44.9 (16.6-155.9) |
| Sex, n (%) | |
| Female | 20 (29) |
| Male | 49 (71) |
| FAB classification, n (%) | |
| M0 | 5 (7) |
| M1 | 11 (16) |
| M2 | 14 (20) |
| M3 | 2 (3) |
| M4 | 16 (23) |
| M5 | 12 (17) |
| M6 | 1 (1) |
| M7 | 2 (3) |
| Unknown | 6 (9) |
| Cytogenetic subgroups | |
| AML-ETO1 | 7 (10) |
| MLL | 5 (7) |
| PML-RAR | 0 (0) |
| CBF-MYH | 2 (3) |
| CN-AML | 13 (19) |
| Other | 22 (32) |
| Unknown | 20 (29) |
WBC indicates white blood cell; FAB, French-American-British morphology classification; and CN-AML, cytogenetically normal acute myeloid leukemia.